Use of Cardiac Imaging in HFpEF Clinical Trials: Should it be Part of Enrollment Criteria or Trial End Points?

Time: 2:00 pm
day: Day One


  • Understand how cardiac imaging may provide supporting evidence for the diagnosis of HFpEF, eventhough the sensitivity and specificity of cardiac imaging for establishing this diagnosis are still uncertain
  • Assess how imaging has the potential to be very useful in identifying subtypes of HFpEF (phenotypes or phenogroups) and thus, allow a more targeted or personalized treatment approach
  • Learn how changes in cardiac structure or function identified by certain imaging tests may be appropriate endpoints for clinical trials, and may be easier to use than clinical endpoints